Professional Documents
Culture Documents
Immunothrapy
Immunothrapy
gastric cancer
Dr Adham Abutaha
Siham weredat
Gastric cancer is the fifth most common cancer and the third
most common cause of cancer death globally.
Checkpoint inhibitors work by blocking the receptors that cancer cells use to
send signals to T-cells. When the signal is blocked, T-cells may be better able
to differentiate a cancer cell from a healthy cell and launch an attacks
Some of biomarkers that found in cancer cell cancers
cells that may indicate the drug will produce a
positive
outcome.
1-nivolumab
2- prmbrolizumab
3- avelumab
4- dostarilmab
Nivolumab
-Nivolumab is approved as an option for third- or later-line
treatment of advanced gastric/gastroesophageal junction
(3) in cases where CPS < 5 or unknown, the decision to treat with
nivolumab plus chemotherapy or chemotherapy alone should
be taken with consideration to the patient’s overall fitness
and access to subsequent therapies.
.
Anti-PD-1 Antibody Plus HER2-
Targeted Therapy